Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | ESMO 2023 highlights in genitourinary cancer

Bradley A. McGregor • 22 Oct 2023
ESMO 2023
Bladder Cancer Genitourinary Cancer Urothelial Carcinoma Antibodies Enfortumab vedotin Pembrolizumab Sacituzumab govitecan
KEYNOTE-A39

Bradley A. McGregor, MD, Dana Farber Cancer Institute, Boston, MA, shares highlights from the European Society for Medical Oncology (ESMO) 2023 Congress with regard to genitourinary cancers, including data that shows that enfortumab vedotin plus pembrolizumab significantly improves overall-survival (OS) and progression-free survival (PFS) compared to platinum-based chemotherapy in patients with metastatic urothelial carcinoma (KEYNOTE-A39; NCT04223856). This interview took place at the ESMO 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Bradley A. McGregor

5:44
DAD: sacituzumab govetican + enfortumab vedotin as a 2L therapy for mUC
Bradley A. McGregor • 22 Oct 2023
1:58
Phase II trial of nivolumab plus ipilimumab in advanced bladder cancer of variant histologies
Bradley A. McGregor • 22 Oct 2023
0:38
Novel combined ADCs in metastatic urothelial carcinoma: insights from ESMO 2023
Bradley A. McGregor • 22 Oct 2023

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals